Scientists create universal nasal spray vaccine that protects against COVID, flu, and pneumonia

For decades, the scientific community has been captivated by the elusive vision of a universal vaccine—a single prophylactic agent capable of shielding humanity from a vast array of infectious threats, a goal that has often resided in the realm of scientific mythology. Now, a groundbreaking development from researchers at Stanford Medicine, in collaboration with esteemed institutions, signals a monumental stride toward realizing this long-sought aspiration. A new experimental universal vaccine, administered intranasally, has demonstrated robust and wide-ranging protection in the lungs of mice against a broad spectrum of respiratory viruses, bacteria, and even common allergens, with effects lasting for months.

This pioneering research, detailed in a study published on February 19 in the prestigious journal Science, marks a significant departure from traditional vaccinology paradigms. The findings illustrate that vaccinated mice were effectively protected against a formidable list of pathogens, including SARS-CoV-2 and other coronaviruses, virulent hospital-acquired bacteria such as Staphylococcus aureus and Acinetobacter baumannii, and even common allergens like house dust mites. Dr. Bali Pulendran, PhD, the Violetta L. Horton Professor II and professor of microbiology and immunology, and senior author of the study, expressed that the observed level of protection across such diverse respiratory challenges considerably surpassed initial expectations. The lead author of this pivotal study is Dr. Haibo Zhang, PhD, a postdoctoral scholar in Dr. Pulendran’s laboratory. Should these remarkable results translate successfully to human trials, a single, easily administered nasal vaccine could potentially revolutionize public health, potentially obviating the need for multiple annual vaccinations against seasonal respiratory illnesses and offering rapid, comprehensive protection in the face of emerging pandemic threats.

The Evolving Imperative: Rethinking Traditional Vaccine Strategies

Since the late 18th century, when Edward Jenner pioneered the concept of vaccination by using cowpox to confer immunity against smallpox, the fundamental strategy underpinning vaccine development has largely revolved around antigen specificity. This classical approach involves presenting the immune system with a distinct, recognizable fragment of a pathogen—such as the spike protein of SARS-CoV-2—enabling the body to develop targeted antibodies and T cells that can swiftly identify and neutralize the actual threat upon subsequent exposure. Dr. Pulendran notes that this principle has been the bedrock of vaccinology for over 230 years.

However, the efficacy of this antigen-specific paradigm faces persistent challenges from the relentless evolutionary capacity of many pathogens. Viruses, in particular, are notorious for their rapid mutation rates, frequently altering the surface structures that vaccines target. This phenomenon, known as antigenic drift and shift in influenza viruses, necessitates the annual reformulation and administration of updated COVID-19 boosters and seasonal flu shots. As Dr. Pulendran aptly describes, "It’s becoming increasingly clear that many pathogens are able to quickly mutate. Like the proverbial leopard that changes its spots, a virus can change the antigens on its surface." This constant arms race between pathogen evolution and vaccine development underscores the limitations of purely antigen-specific approaches.

Historically, efforts to develop broader vaccines have primarily focused on achieving protection against entire viral families—for instance, a pan-coronavirus vaccine or a universal influenza vaccine—by targeting conserved viral components that mutate less frequently. The audacious idea of a single vaccine providing defense against a multitude of unrelated pathogens, spanning viruses, bacteria, and allergens, has generally been considered scientifically implausible. Dr. Pulendran candidly admits, "We were interested in this idea because it sounded a bit outrageous. I think nobody was seriously entertaining that something like this could ever be possible." This sentiment highlights the truly disruptive nature of the current Stanford research.

A Paradigm Shift: Activating Integrated Immunity for Enduring Protection

The innovative strategy employed by this new experimental vaccine fundamentally diverges from traditional methods. Rather than mimicking a specific viral or bacterial component, it aims to replicate the intricate communication signals exchanged between immune cells during an infection. By doing so, it orchestrates a synchronized and prolonged response that integrates the body’s two primary defense systems: innate and adaptive immunity.

Most conventional vaccines predominantly stimulate the adaptive immune system, which is responsible for generating pathogen-specific antibodies and specialized T cells that retain immunological memory, often for years. The innate immune system, in contrast, represents the body’s first line of defense, responding within minutes of an infection. It deploys a diverse array of cells, including dendritic cells, neutrophils, and macrophages, which broadly attack perceived threats without prior exposure. However, the innate immune response is typically short-lived, fading within days.

Dr. Pulendran’s team was particularly intrigued by the inherent versatility and broad-spectrum capabilities of the innate system. "What’s remarkable about the innate system is that it can protect against a broad range of different microbes," he explains. While innate immunity is generally transient, there have been intriguing hints that its effects can occasionally persist longer. A notable example is the Bacillus Calmette-Guerin (BCG) vaccine, originally developed for tuberculosis and administered to approximately 100 million newborns globally each year. Numerous observational studies have suggested that BCG vaccination may reduce infant mortality from other infections, implying a form of extended cross-protection, though the precise mechanisms remained largely elusive and results sometimes varied.

In a pivotal discovery in 2023, Dr. Pulendran’s group elucidated the mechanism behind this unexpected cross-protection in mice. They found that the BCG vaccine triggered both innate and adaptive immune responses, but uniquely, the innate response remained active for an extended period of months. Crucially, the researchers identified that T cells, recruited to the lungs as part of the adaptive response, were actively sending signals that maintained the activation of innate immune cells. "Those T cells were providing a critical signal to keep the activation of the innate system, which typically lasts for a few days or a week, but in this case, it could last for three months," Dr. Pulendran clarified. This sustained heightened innate activity conferred protection against SARS-CoV-2 and other coronaviruses in mice. The team pinpointed specific cytokines—signaling molecules—released by these T cells as the critical activators of pathogen-sensing receptors, known as toll-like receptors (TLRs), on innate immune cells.

This foundational work laid the intellectual groundwork for the current breakthrough. "In that paper, we speculated that since we now know how the tuberculosis vaccine is mediating its cross-protective effects, it would be possible to make a synthetic vaccine, perhaps a nasal spray, that has the right combination of toll-like receptor stimuli and some antigen to get the T cells into the lungs," Dr. Pulendran recounted. "Fast forward two and a half years and we’ve shown that exactly what we had speculated is feasible in mice." This demonstrates a clear chronological progression of discovery, from mechanistic understanding to synthetic application.

The Nasal Vaccine: A Master Orchestrator of Lung Immunity

The new formulation, currently designated GLA-3M-052-LS+OVA, is ingeniously engineered to mimic the T cell-derived signals that potently stimulate innate immune cells specifically within the lungs. Crucially, it also incorporates a harmless antigen, ovalbumin (OVA), a protein derived from egg white. This OVA serves a dual purpose: it draws T cells into the lung tissue, and it helps to sustain the boosted innate immune response for an impressive duration of weeks to months. The choice of intranasal delivery is particularly strategic, as it targets the primary entry point for most respiratory pathogens, fostering a localized and robust immune defense.

In the meticulously designed study, mice received the experimental vaccine as droplets administered intranasally. Some cohorts received multiple doses spaced one week apart. Following vaccination, each mouse was subsequently challenged with a respiratory virus. The results were compelling: with just three doses, the vaccinated mice maintained protection against SARS-CoV-2 and other coronaviruses for at least three months. In stark contrast, unvaccinated control mice exhibited severe weight loss—a clear indicator of significant illness—and frequently succumbed to the infections. Their lungs showed extensive inflammation and harbored high viral loads. Conversely, vaccinated mice experienced significantly less weight loss, all survived, and their lung tissues contained remarkably low viral levels.

Dr. Pulendran characterized the effect as a "double whammy," highlighting the synergistic action of the integrated immune response. The sustained innate response alone dramatically reduced viral levels in the lungs by an astonishing 700-fold. Any residual viruses that managed to bypass this formidable first layer of defense were then swiftly met by an accelerated adaptive response. "The lung immune system is so ready and so alert that it can launch the typical adaptive responses—virus-specific T cells and antibodies—in as little as three days, which is an extraordinarily short length of time," Dr. Pulendran elaborated. "Normally, in an unvaccinated mouse, it takes two weeks." This rapid adaptive response is critical for quickly clearing any remaining infection and preventing severe disease.

Beyond Viruses: Protection Against Bacterial Pathogens and Allergens

Encouraged by the vaccine’s robust performance against viral infections, the research team extended their investigation to include bacterial respiratory pathogens. They tested the vaccine’s efficacy against two common and often dangerous hospital-acquired infections: Staphylococcus aureus and Acinetobacter baumannii. Both bacteria are significant public health concerns, with S. aureus being a leading cause of bloodstream infections, pneumonia, and surgical site infections, often complicated by antibiotic resistance (e.g., MRSA). A. baumannii is a notorious multidrug-resistant pathogen, frequently associated with ventilator-associated pneumonia and severe infections in immunocompromised patients. The results were equally impressive: vaccinated mice were protected from these bacterial infections for approximately three months, demonstrating the vaccine’s broad antibacterial potential.

The researchers then pondered, "What else could go in the lung?" The answer led them to another major respiratory challenge: allergens. To explore this facet, the team exposed vaccinated mice to a protein derived from house dust mites, a ubiquitous allergen and a common trigger for allergic asthma. Allergic reactions typically involve a specific type of immune response known as a Th2 response, characterized by inflammation and mucus production. Unvaccinated mice developed a strong Th2 response and accumulated significant mucus in their airways, consistent with an allergic reaction. In stark contrast, vaccinated mice exhibited a much weaker Th2 response and maintained clear airways, suggesting a potential role for this universal vaccine in mitigating allergic asthma. "I think what we have is a universal vaccine against diverse respiratory threats," Dr. Pulendran concluded, encapsulating the profound breadth of their discovery.

Implications for Public Health and Pandemic Preparedness

The implications of this breakthrough are far-reaching and potentially transformative for global public health. The concept of a single vaccine offering broad-spectrum protection against a multitude of respiratory pathogens could fundamentally reshape our approach to infectious disease prevention and pandemic preparedness.

Simplified Vaccination Schedules: Imagine a future where a single nasal spray, administered once or twice a year, could provide comprehensive protection against seasonal influenza strains, various coronaviruses (including COVID-19 variants), respiratory syncytial virus (RSV), common cold viruses, and even bacterial pneumonia. This would dramatically simplify vaccination schedules, improve vaccine uptake, and reduce the logistical burden on healthcare systems.

Enhanced Pandemic Preparedness: The rapid emergence of novel pathogens, as exemplified by the SARS-CoV-2 pandemic, highlights the urgent need for agile and broad-acting countermeasures. A universal respiratory vaccine, capable of conferring rapid, non-specific protection, could serve as a critical first line of defense during the crucial period before pathogen-specific vaccines can be developed, tested, and deployed. This "bridge" immunity could significantly blunt the initial wave of infection, reducing morbidity and mortality and buying precious time.

Addressing Antimicrobial Resistance: The rising tide of antibiotic-resistant bacteria, particularly in healthcare settings, poses an existential threat to modern medicine. Preventing bacterial infections through vaccination is a highly effective strategy to reduce antibiotic use and, consequently, slow the development and spread of resistance. The observed protection against S. aureus and A. baumannii suggests this vaccine could play a vital role in combating the antimicrobial resistance crisis.

Alleviating Allergic Burden: For millions suffering from allergic asthma triggered by airborne allergens like dust mites, a vaccine that could dampen hyper-responsive immune reactions could significantly improve quality of life and reduce healthcare costs associated with chronic respiratory conditions.

Economic and Societal Impact: Respiratory infections impose an enormous economic burden globally, encompassing healthcare costs, lost productivity due to illness, and the disruption of daily life. A universal vaccine has the potential to substantially reduce these costs, contributing to healthier populations and more resilient societies.

The Road Ahead: Human Trials and Future Availability

The next critical phase for this groundbreaking research involves transitioning from preclinical mouse studies to human testing, commencing with a Phase I safety trial. This initial trial will assess the vaccine’s safety profile and tolerability in humans. If these results are positive, larger, more extensive studies will follow, potentially including controlled human infection models to evaluate efficacy. Dr. Pulendran optimistically estimates that if adequate funding is secured and trials proceed favorably, a universal respiratory vaccine could potentially become available to the public within five to seven years. He anticipates that two doses delivered as a nasal spray could be sufficient to confer robust protection in people.

The research team, a collaborative effort, included scientists from Emory University School of Medicine, the University of North Carolina at Chapel Hill, Utah State University, and the University of Arizona, underscoring the interdisciplinary nature of this scientific endeavor. Funding for this pivotal work was provided by significant grants from the National Institutes of Health (grant AI167966), alongside support from the Violetta L. Horton Professor endowment, the Soffer Fund endowment, and Open Philanthropy.

"Imagine getting a nasal spray in the fall months that protects you from all respiratory viruses including COVID-19, influenza, respiratory syncytial virus and the common cold, as well as bacterial pneumonia and early spring allergens," Dr. Pulendran muses, painting a vivid picture of the future. "That would transform medical practice." This vision, once deemed mythical, now stands on the precipice of becoming a tangible reality, promising a future where humanity is better equipped to defend itself against the ever-present threat of respiratory illnesses. The journey from laboratory discovery to global health solution is long and arduous, but the initial steps taken by the Stanford team represent a beacon of hope for a healthier, more resilient world.